Abstract
In 2015 the National Institute for Health and Care Excellence (NICE) recommended dexamethasone intravitreal implant (DEX) for the treatment of diabetic macular oedema (DMO) where non-corticosteroid therapy is unsuitable or insufficiently responsive in pseudophakic eyes (TA349). However, DEX was not considered cost effective compared with ‘watch and wait’ (w&w) in phakic eyes. In 2019, NICE acknowledged that anti-vascular endothelial growth factors (anti-VEGFs) and laser treatments are frequently administered to insufficient responders given a lack of recommended alternatives (TA613).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
